Health
Affinity’s COVID-19 antibodies ready for clinical trials – BSA bureau
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
The neutralizing antibodies under trial are potentially useful for vaccine development for an apid therapy or to protect people in high-risk situations such as healthcare workers or people in direct contact with COVID patients.
Melbourne-based Affinity Biosciences Pty Ltd (Affinity) has lodged a pre-publication submission to the scientific journal, ‘mAbs’, detailing its results and observations relating to the discovery of potent antibodies against COVID-19.
This can be found at the link,’Anti…
-
Business24 hours agoThese ASX 200 shares could rise 50% to 60%
-
General23 hours agoAustralia’s Myanmar community mourns earthquake losses
-
General22 hours agoPeter Dutton partially walks back public service work-from-home vow
-
Noosa News20 hours agoDisaster relief packages announced for flood-stricken western Queensland